Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/30/2024 | $85.00 | Outperform | Wedbush |
| 7/22/2024 | $80.00 | Buy | H.C. Wainwright |
| 6/26/2024 | $85.00 | Buy | B. Riley Securities |
| 6/3/2024 | $60.00 → $80.00 | Outperform | Oppenheimer |
| 5/13/2024 | $77.00 | Outperform | RBC Capital Mkts |
| 3/6/2024 | $4.00 → $46.00 | Hold → Buy | Jefferies |
NORWOOD, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 7th Annual Evercore HealthCONx Conference to be held December 3-5, 2024 in Coral Gables, FL. 7th Annual Evercore HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3, 2024Time: 4:15 p.m. ETWebcast: Click here About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious
NORWOOD, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference to be held November 19-21, 2024 in London, UK. Jefferies London Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 19, 2024Time: 10:30 a.m. GMTWebcast: Click here About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious ill
Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701) - First data expected to be presented in Q1 2025Presented New CRB-913 Pre-Clinical Data at Obesity Week 2024 - Phase 1 Trial Expected to Commence in Q1 2025 NORWOOD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended September 30, 2024. "We continue to make steady and significant progress across our pipeline," said Yuval Cohen, Ph.D.,
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h
NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors. "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Our recent license agreement for CRB-701 has helped cement our position as a precision o
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
Wedbush initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $85.00
H.C. Wainwright resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $80.00
B. Riley Securities initiated coverage of Corbus Pharma with a rating of Buy and set a new price target of $85.00
HC Wainwright & Co. analyst Andrew Fein reinstates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and announces $80 price target.
GAINERS: Green Growth Brands (OTC:GGBXF) shares closed up 9900.00% at $0.0001 Rocky Mountain High (OTC:RMHB) shares closed up 33.33% at $0.02 SOL Glb Inv (OTC:SOLCF) shares closed up 19.57% at $0.05 Affinor Growers (OTC:RSSFF) shares closed up 19.12% at $0.08 Pharmadrug (OTC:LMLLF) shares closed up 18.52% at $0.02 1933 Industries (OTC:TGIFF) shares closed up 8.23% at $0.01 Cansortium (OTC:CNTMF) shares closed up 7.14% at $0.15 CV Sciences (OTC:CVSI) shares closed up 7.12% at $0.06 CLS Holdings USA (OTC:CLSH) shares closed up 6.26% at $0.04 Cipher Pharmaceuticals (OTC:CPHRF) shares closed up 5.67% at $6.43 Body and Mind (OTC:BMMJ) shares closed up 5.40% at $0.03 OrganiGram Holdings (NASDAQ:O
GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing. The Maryland-based company’s shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview. Goldman Sachs analyst Matthew Sykes attributes much of GeneDX’s positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person’s DNA to find genetic variations. Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance “We remain o
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)